1. Clinical Activity of the Oral ALK Inhibitor,Clinical Activity of the Oral ALK Inhibitor, Crizotinib (PF-02341066), in Patients withCrizotinib (PF-02341066), in Patients…
Lucio Crinò, MD Silvestrini Hospital Perugia, Italy ALK INHIBITORS IN LUNG CANCER THERAPY * Identification of Aberrant Forms of the Anaplastic Lymphoma Kinase Expressed…
ALK in lung cancer: Past, present, and future ALK in lung cancer: Past, present, and future Gene Mutations in Lung Adenocarcinomas 17 years ago…… 2;5 chromosomal translocation…